From selenium to selenoproteins: Synthesis, identity, and their role in human health

Antioxidants and Redox Signaling

Volumn 9, Issue 7, 2007, Pages 775-806

  Papp, Laura Vanda ^a,b   Lu, Jun ^c   Holmgren, Arne ^c   Khanna, Kum Kum ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; ANTINEOPLASTIC AGENT; ANTITHYROID AGENT; BINDING PROTEIN; CISPLATIN; CURCUMIN; DIAZIQUONE; DIMETHYLBENZ[A]ANTHRACENE; DOXORUBICIN; EBSELEN; FLAVONOID; GADOLINIUM TEXAPHYRIN; GLUTATHIONE PEROXIDASE; METHIONINE SULFOXIDE REDUCTASE B; MYRICETIN; NITROSOUREA; PLACEBO; POLYPHENOL; PROPYLTHIOURACIL; QUERCETIN; RIBOSOME PROTEIN; SELENIUM; SELENOAMINO ACID; SELENOCYSTEINE; SELENOPROTEIN; SELENOPROTEIN P; SELENOPROTEIN W; THIOREDOXIN REDUCTASE; THYROID HORMONE; THYROXINE DEIODINASE;

ADULT; AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; AUTOIMMUNE DISEASE; BIOSYNTHESIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CLINICAL TRIAL; COLORECTAL CANCER; CONGENITAL HYPOTHYROIDISM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG TARGETING; ENZYME ACTIVITY; ESOPHAGUS CANCER; GENE MUTATION; GRAVES DISEASE; HASHIMOTO DISEASE; HEPATITIS B; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IODINE DEFICIENCY; KIDNEY CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MOUSE; MULTICENTER STUDY; NONHUMAN; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW; SELENIUM DEFICIENCY; SIGNAL TRANSDUCTION; SKIN CANCER; STOMACH CANCER; THYROID GLAND; TRANSCRIPTION REGULATION;

ANIMALS; GLUTATHIONE PEROXIDASE; HUMANS; MODELS, BIOLOGICAL; SELENIUM; SELENOPROTEINS; THIOREDOXIN REDUCTASE (NADPH);

EID: 34250318625     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2007.1528     Document Type: Review

References (356)

1. Akesson B, Bellew T, and Burk RF. Purification of selenoprotein P from human plasma. Biochim Biophys Acta 1204: 243-249, 1994.
2. Al-Taie OH, Uceyler N, Eubner U, Jakob F, Mork H, Scheurlen M, Brigelius-Flohe R, Schottker K, Abel J, Thalheimer A, Katzenberger T, Illert B, Melcher R, and Kohrle J. Expression profiling and genetic alterations of the selenoproteins GI-GPx and SePP in colorectal carcinogenesis. Nutr Cancer 48: 6-14, 2004.
3. Aliev G, Smith MA, Seyidov D, Neal ML, Lamb BT, Nunomura A, Gasimov EK, Vinters HV, Perry G, LaManna JC, and Friedland RP. The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer's disease. Brain Pathol 12: 21-35, 2002.
4. Allamand V, Richard P, Lescure A, Ledeuil C, Desjardin D, Petit N, Gartioux C, Ferreiro A, Krol A, Pellegrini N, Urtizberea JA, and Guicheney P. A single homozygous point mutation in a 3′-untranslated region motif of selenoprotein N mRNA causes SEPN1-related myopathy. EMBO Rep 7: 450-454, 2006.
5. Allmang C, Carbon P, and Krol A. The SBP2 and 15.5 kD/Snu13p proteins share the same RNA binding domain: identification of SBP2 amino acids important to SECIS RNA binding. RNA 8: 1308-1318, 2002.
6. Amantana A, Vorachek WR, Butler JA, Ream W, and Whanger PD. Identification of putative transcription factor binding sites in rodent selenoprotein W promoter. J Inorg Biochem 98: 1513-1520, 2004.
7. Ambroziak M, Pachucki J, Stachlewska-Nasfeter E, Nauman J, and Nauman A. Disturbed expression of type 1 and type 2 iodothyronine deiodinase as well as titf1/nkx2-1 and pax-8 transcription factor genes in papillary thyroid cancer. Thyroid 15: 1137-1146, 2005.
8. Andersson M, Holmgren A, and Spyrou G. NK-lysin, a disulfide-containing effector peptide of T-lymphocytes, is reduced and inactivated by human thioredoxin reductase: implication for a protective mechanism against NK-lysin cytotoxicity. J Biol Chem 271: 10116-10120, 1996.
9. Apostolou S, Klein JO, Mitsuuchi Y, Shetler JN, Poulikakos PI, Jhanwar SC, Kruger WD, and Tesla JR. Growth inhibition and induction of apoptosis in mesothelioma cells by selenium and dependence on selenoprotein SEP15 genotype. Oncogene 23: 5032-5040, 2004.
10. Arner ES and Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267: 6102-6109, 2000.
11. Arnér ES, Nakamura H, Sasada T, Yodoi J, Holmgren A, and Spyrou G. Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex. Free Radic Biol Med 31: 1170-1178, 2001.
12. Arner ES, Nordberg J, and Holmgren A. Efficient reduction of lipoamide and lipoic acid by mammalian thioredoxin reductase. Biochem Biophys Res Commun 225: 268-274, 1996.
13. Arner ES, Zhong L, and Holmgren A. Preparation and assay of mammalian thioredoxin and thioredoxin reductase. Methods Enzymol 300: 226-239, 1999.
14. Arscott LD, Gromer S, Schirmer RH, Becker K, and Williams CH Jr. The mechanism of thioredoxin reductase from human placenta is similar to the mechanisms of lipoamide dehydrogenase and glutathione reductase and is distinct from the mechanism of thioredoxin reductase from Escherichia coli. Proc Natl Acad Sci U S A 94: 3621-3626, 1997.
15. Arteel GE, Briviba K, and Sies H. Function of thioredoxin reductase as a peroxynitrite reductase using selenocystine or ebselen. Chem Res Toxicol 12: 264-269, 1999.
16. Arteel GE, Mostert V, Oubrahim H, Briviba K, Abel J, and Sies H. Protection by selenoprotein P in human plasma against peroxynitrite-mediated oxidation and nitration. Biol Chem 379: 1201-1205, 1998.
17. Arthur JR. The glutathione peroxidases. Cell Mol Life Sci 57: 1825-1835, 2000.
18. Atkinson JB, Hill KE, and Burk RF. Centrilobular endothelial cell injury by diquat in the selenium-deficient rat liver. Lab Invest 81: 193-200, 2001.
19. Banning A, Deubel S, Kluth D, Zhou Z, and Brigelius-Flohe R. The GI-GPx gene is a target for Nrf2. Mol Cell Biol 25: 4914-4923, 2005.
20. Bansal MP, Cook RG, Danielson KG, and Medina D. A 14-kilo-dalton selenium-binding protein in mouse liver is fatty acid-binding protein. J Biol Chem 264: 13780-13784, 1989.
21. Bansal MP, Mukhopadhyay T, Scott J, Cook RG, Mukhopadhyay R, and Medina D. DNA sequencing of a mouse liver protein that binds selenium: implications for selenium's mechanism of action in cancer prevention. Carcinogenesis 11: 2071-2073, 1990.
22. Baqui M, Botero D, Gereben B, Curcio C, Harney JW, Salvatore D, Sorimachi K, Larsen PR, and Bianco AC. Human type 3 iodothyronine selenodeiodinase is located in the plasma membrane and undergoes rapid internalization to endosomes. J Biol Chem 278: 1206-1211, 2003.
23. Baqui MM, Gereben B, Harney JW, Larsen PR, and Bianco AC. Distinct subcellular localization of transiently expressed types 1 and 2 iodothyronine deiodinases as determined by immunofluorescence confocal microscopy. Endocrinology 141: 4309-4312, 2000.
24. Bates JM, Spate VL, Morris JS, St Germain DL, and Galton VA. Effects of selenium deficiency on tissue selenium content, deiodinase activity, and thyroid hormone economy in the rat during development. Endocrinology 141: 2490-2500, 2000.
25. Beck MA, Esworthy RS, Ho YS, and Chu FF. Glutathione peroxidase protects mice from viral-induced myocarditis. FASEB J 12: 1143-1149, 1998.
26. Behne D and Kyriakopoulos A. Mammalian selenium-containing proteins. Annu Rev Nutr 21: 453-473, 2001.
27. Behne D, Kyriakopoulos A, Kaleklosch M, Weiss-Nowak C, Pfeifer H, Gessner H, and Hammel C. Two new selenoproteins found in the prostatic glandular epithelium and in the spermatid nuclei. Biomed Environ Sci 10: 340-345, 1997.
28. Beilstein MA, Vendeland SC, Barofsky E, Jensen ON, and Whanger PD. Selenoprotein W of rat muscle binds glutathione and an unknown small molecular weight moiety. J Inorg Biochem 61: 117-124, 1996.
29. Berlett BS and Stadtman ER. Protein oxidation in aging, disease, and oxidative stress. J Biol Chem 272: 20313-20316, 1997.
30. Berry MJ, Banu L, Chen YY, Mandel SJ, Kieffer JD, Harney JW, and Larsen PR. Recognition of UGA as a selenocysteine codon in type 1 deiodinase requires sequences in the 3′untranslated region. Nature 353: 273-276, 1991.
31. Berry MJ, Banu L, Harney JW, and Larsen PR. Functional characterization of the eukaryotic SECIS elements which direct selenocysteine insertion at UGA codons. UMBO J 12: 3315-3322, 1993.
32. Bianco AC and Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest 116: 2571-2579, 2006.
33. Bianco AC and Larsen PR. Cellular and structural biology of the deiodinases. Thyroid 15: 777-786, 2005.
34. Bianco AC, Salvatore D, Gereben B, Berry MJ, and Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 23: 38-89, 2002.
35. Biterova El, Turanov AA, Gladyshev VN, and Barycki JJ. Crystal structures of oxidized and reduced mitochondrial thioredoxin reductase provide molecular details of the reaction mechanism. Proc Natl Acad Sci U S A 102: 15018-15023, 2005.
36. Bjorkhem-Bergman L, Torndal UB, Eken S, Nystrom C, Capitanio A, Larsen EH, Bjornstedt M, and Eriksson LC. Selenium prevents tumor development in a rat model for chemical carcinogenesis. Carcinogenesis 26: 125-131, 2005.
37. Bjornstedt M, Hamberg M, Kumar S, Xue J, and Holmgren A. Human thioredoxin reductase directly reduces lipid hydroperoxides by NADPH and selenocystine strongly stimulates the reaction via catalytically generated selenols. J Biol Chem 270: 11761-11764, 1995.
38. Bjornstedt M, Kumar S, and Holmgren A. Selenodiglutathione is a highly efficient oxidant of reduced thioredoxin and a substrate for mammalian thioredoxin reductase. J Biol Chem 267: 8030-8034, 1992.
39. Bock A. Biosynthesis of selenoproteins: an overview. Biofactors 11: 77-78, 2000.
40. Bock A. Molecular biology: invading the genetic code. Science 292: 453-454, 2001.
41. Borchert A, Savaskan NE, and Kuhn H. Regulation of expression of the phospholipid hydroperoxide/sperm nucleus glutathione peroxidase gene: tissue-specific expression pattern and identification of functional cis- and trans-regulatory elements. J Biol Chem 278: 2571-2580, 2003.
42. Bosl MR, Takaku K, Oshima M, Nishimura S, and Taketo MM. Early embryonic lethality caused by targeted disruption of the mouse selenocysteine tRNA gene (Trsp). Proc Natl Acad Sci U S A 94: 5531-5534, 1997.
43. Bradshaw TD, Matthews CS, Cookson J, Chew EH, Shah M, Bailey K, Monks A, Harris E, Westwell AD, Wells G, Laughton CA, and Stevens MF. Elucidation of thioredoxin as a molecular target for antitumor quinols. Cancer Res 65: 3911-3919, 2005.
44. Brenneisen P, Steinbrenner H, and Sies H. Selenium, oxidative stress, and health aspects. Mol Aspects Med 26: 256-267, 2005.
45. Brigelius-Flohe R. Glutathione peroxidases and redox-regulated transcription factors. Biol Chem 387: 1329-1335, 2006.
46. Brigelius-Flohe R. Tissue-specific functions of individual glutathione peroxidases. Free Radic Biol Med 27: 951-965, 1999.
47. Brigelius-Flohe R and Banning A. Part of the series: from dietary antioxidants to regulators in cellular signaling and gene regulation: sulforaphane and selenium, partners in adaptive response and prevention of cancer. Free Radic Res 40: 775-787, 2006.
48. Brigelius-Flohe R, Wingler K, and Muller C. Estimation of individual types of glutathione peroxidases. Methods Enzymol 347: 101-112, 2002.
49. Brown LM, Helmke SM, Hunsucker SW, Netea-Maier RT, Chiang SA, Heinz DE, Shroyer KR, Duncan MW, and Haugen BR. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol Carcinog 45: 613-626, 2006.
50. Burk RF, and Hill KE. Selenoprotein P: a selenium-rich extracellular glycoprotein. J Nutr 124: 1891-1897, 1994.
51. Burk RF and Hill KE. Selenoprotein P: an extracellular protein with unique physical characteristics and a role in selenium homeostasis. Annu Rev Nutr 25: 215-235, 2005.
52. Caban K and Copeland PR. Size matters: a view of selenocysteine incorporation from the ribosome. Cell Mol Life Sci 63: 73-81, 2006.
53. Callebaut I, Curcio-Morelli C, Mornon JP, Gereben B, Buettner C, Huang S, Castro B, FonsecaTL, Harney JW, Larsen PR, and Bianco AC. The iodothyronine selenodeiodinases are thioredoxin-fold family proteins containing a glycoside hydrolase clan GH-A-like structure. J Biol Chem 278: 36887-36896, 2003.
54. Calvo A, Xiao N, Kang J, Best CJ, Leiva I, Emmert-Buek MR, Jorcyk C, and Green JE. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors. Cancer Res 62: 5325-5335, 2002.
55. Carlson BA and Hatfield DL. Transfer RNAs that insert selenocysteine. Methods Enzymol 347: 24-39, 2002.
56. Carlson BA, Novoselov SV, Kumaraswamy E, Lee BJ, Anver MR, Gladyshev VN, and Hatfield DL. Specific excision of the selenocysteine tRNA[Ser]Sec (Trsp) gene in mouse liver demonstrates an essential role of selenoproteins in liver function. J Biol Chem 279: 8011-8017, 2004.
57. Carlson BA, Xu XM, Gladyshev VN, and Hatfield DL. Selective rescue of selenoprotein expression in mice lacking a highly specialized methyl group in selenocysteine tRNA. J Biol Chem 280: 5542-5548, 2005.
58. Carlson BA, Xu XM, Kryukov GV, Rao M, Berry MJ, Gladyshev VN, and Hatfield DL. Identification and characterization of phosphoseryl-tRNA[Ser]Sec kinase. Proc Natl Acad Sci U S A 101: 12848-12853, 2004.
59. Castellano S, Lobanov AV, Chapple C, Novoselov SV, Albrecht M, Hua D, Lescure A, Lengauer T, Krol A, Gladyshev VN, and Guigo R. Diversity and functional plasticity of eukaryotic selenoproteins: identification and characterization of the SelJ family. Proc Natl Acad Sci U S A 102: 16188-16193, 2005.
60. Chambers I, Frampton J, Goldfarb P, Affara N, McBain W, and Harrison PR. The structure of the mouse glutathione peroxidase gene: the selenocysteine in the active site is encoded by the 'termination' codon, TGA. EMBO J 5: 1221-1227, 1986.
61. Chang EY, Son SK, Ko HS, Back SH, Kim JH, and Kim JR. Induction of apoptosis by the overexpression of an alternative splicing variant of mitochondrial thioredoxin reductase. Free Radic Biol Med 39: 1666-1675, 2005.
62. Chang PW Tsui SK, Liew C, Lee CC, Waye MM, and Fung KP. Isolation, characterization, and chromosomal mapping of a novel cDNA clone encoding human selenium binding protein. J Cell Biochem 64: 217-224, 1997.
63. Chavatte L, Brown BA, and Driscoll DM. Ribosomal protein L30 is a component of the UGA-selenocysteine recoding machinery in eukaryotes. Nat Struct Mol Biol 12: 408-416, 2005.
64. Chen G, Wang H, Miller CT, Thomas DG, Gharib TG, Misck DE, Giordano TJ, Orringer MB, Hanash SM, and Beer DG. Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. J Pathol 202: 321-329, 2004.
65. Chen J and Berry MJ. Selenium and selenoproteins in the brain and brain diseases. J Neurochem 86: 1-12, 2003.
66. Cheng W, Fu YX, Porres JM, Ross DA, and Lei XG. Selenium-dependent cellular glutathione peroxidase protects mice against a pro-oxidant-induced oxidation of NADPH, NADH, lipids, and protein. FASEB J 13: 1467-1475, 1999.
67. Cheng WH, Ho YS, Valentine BA, Ross DA, Combs GF Jr. and Lei XG. Cellular glutathione peroxidase is the mediator of body selenium to protect against paraquat lethality in transgenic mice. J Nutr 128: 1070-1076, 1998.
68. Cheng WH, Quimby FW, and Lei XG. Impacts of glutathione peroxidase-1 knockout on the protection by injected selenium against the pro-oxidant-induced liver aponecrosis and signaling in selenium-deficient mice. Free Radic Biol Med 34: 918-927, 2003.
69. Cheung TH, Chung TK, Poon CS, Hampton GM, Wang VW, and Wong YF. Allelic loss on chromosome 1 is associated with tumor progression of cervical carcinoma. Cancer 86: 1294-1298, 1999.
70. Chittum HS, Back HJ, Diamond AM, Fernandez-Salguero P, Gonzalez F, Ohama T, Hatfield DL, Kuehn M, Lee BJ, Hatfield D, and Hampton L. Selenocysteine tRNA[Ser]Sec levels and selenium-dependent glutathione peroxidase activity in mouse embryonic stem cells heterozygous for a targeted mutation in the tRNA[Ser]Sec gene: selenium induces changes in the selenocysteine tRNA[Ser]Sec population in mammalian cells. Biochemists 36: 8634-8639, 1997.
71. Cho YM, Bae SH, Choi BK, Cho SY, Song CW, Yoo JK, and Paik YK. Differential expression of the liver proteome in senescence accelerated mice. Proteomics 3: 1883-1894, 2003.
72. Chu FF, Esworthy RS, Chu PG, Longmate JA, Huyeke MM, Wilczynski S, Doroshow JH, Aranda R, Martin MG, and Binder SW. Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes: mice with combined disruption of Gpx1 and Gpx2 genes have colitis. Cancer Res 64: 962-968, 2004.
73. Chu FF, Esworthy RS, Ho YS, Bermeister M, Swiderek K, and Elliott RW. Expression and chromosomal mapping of mouse Gpx2 gene encoding the gastrointestinal form of glutathione peroxidase. GPX-GI. Biomed Environ Sci 10: 156-162, 1997.
74. Clark LC, Combs GF, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL, Park UK, Sanders BB, Smith CL, and Taylor JR. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial: Nutritional Prevention of Cancer Study Group. JAMA 276: 1957-1963., 1996.
75. Combs GF Jr. Selenium in global food systems. Br J Nutr 85: 517-547, 2001.
76. Conrad M, Jakupoglu C, Moreno SG, Lippl S, Banjac A, Schneider M, Beck H, Hatzopoulos AK, Just U, Sinowatz F, Schmahl W, Chien KR, Wurst W, Bornkamm GW, and Brielmeier M. Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function. Mol Cell Biol 24: 9414-9423, 2004.
77. Conrad M, Moreno SG, Sinowatz F, Ursini F, Kolle S, Roveri A, Brielmeier M, Wurst W, Maiorino M, and Bornkamm GW. The nuclear form of phospholipid hydroperoxide glutathione peroxidase is a protein thiol peroxidase contributing to sperm chromatin stability. Mol Cell Biol 25: 7637-7644, 2005.
78. Contempre B, Dumont JE, Denef JF, and Many MC. Effects of selenium deficiency on thyroid necrosis, fibrosis and proliferation: a possible role in myxedematous cretinism. Eur J Endocrinol 133: 99-109, 1995.
79. Copeland PR and Driscoll DM. Purification, redox sensitivity, and RNA binding properties of SECIS-binding protein, 2: a protein involved in selenoprotein biosynthesis. J Biol Chem 274: 25447-25454, 1999.
80. Copeland PR, Fletcher JE, Carlson BA, Hatfield DL, and Driscoll DM. A novel RNA binding protein, SBP2, is required for the translation of mammalian selenoprotein mRNAs. EMBO J 19: 306-314, 2000.
81. Copeland PR, Stepanik VA, and Driscoll DM. Insight into mammalian selenocysteine insertion: domain structure and ribosome binding properties of Sec insertion sequence binding protein 2. Mol Cell Biol 21: 1491-1498, 2001.
82. Curran JE, Lowett JB, Elliott KS, Gao Y, Gluschenko K, Wang J, Abel Azim DM, Cai G, Mahaney MC, Comuzzic AG, Dyer TD, Walder KR, Zimmet P, MacCluer JW, Collier GR, Kissebah AH, and Blangero J. Genetic variation in selenoprotein S influences inflammatory response. Nat Genet 37: 1234-1241, 2005.
83. Damdimopoulos AE, Miranda-Vizuete A , Treuter E, Gustafsson JA, Spyrou G, Miranda-Vizuete A, and Spyrou G. An alternative splicing variant of the selenoprotein thioredoxin reductase is a modulator of estrogen signaling genomic organization and identification of a novel alternative splicing variant of mouse mitochondrial thioredoxin reductase (TrxR2) gene. J Biol Chem 279: 38721-38729, 2004.
84. Dawson DA, Masayasu H, Graham DI, and Macrae IM. The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat. Neurosci Lett 185: 65-69, 1995.
85. de Haan JB, Bladier C, and Griffiths P. Mice with a homozygous null mutation for the most abundant glutathione peroxidase, Gpx1, show increased susceptibility to the oxidative stress-inducing agetns paraquat and hydrogen peroxide. J Biol Chem 273: 22528-22536, 1998.
86. de Jesus LA, Hoffmann PR, Michaud T, Forry EP, Small-Howard A, Stillwell RJ, Morozova N, Harney JW and Berry MJ. Nuclear assembly of UGA decoding complexes on selenoprotein mRNAs: a mechanism for eluding nonsense-mediated decay? Mol Cell Biol 26: 1795-1805, 2006.
87. de Souza Meyer EL, Dora JM, Wagner MS, and Maia AL. Decreased type 1 iodothyronine deiodinase expression might be an early and discrete event in thyroid cell dedifferentation towards papillary carcinoma. Clin Endocrinol (Oxf) 62: 672-678, 2005.
88. 2 sensing through oxidation of the Yap1 transcription factor. EMBO J 19: 5157-5166, 2000.
89. Diamond AM, Choi IS, Grain PF, Hashizume T, Pomerantz SC, Cruz R, Steer CJ, Hill KE, Burk RF, McCloskey JA, Hatfield DL. Dietary selenium affects methylation of the wobble nucleoside in the anticodon of selenocysteine tRNA([Ser]Sec). J Biol Chem 268: 14215-14223, 1993.
90. Ding F and Grabowski PJ. Identification of a protein component of a mammalian tRNA(Sec) complex implicated in the decoding of UGA as selenocysteine. RNA 5: 1561-1569, 1999.
91. Diwadkar-Navsariwala V, Prins GS, Swanson SM, Birch LA, Ray VH, Hedayat S, Lantvit DL, and Diamond AM. Selenoprotein deficiency accelerates prostate carcinogenesis in a transgenic model. Proc Natl Acad Sci U S A 103; 8179-8184, 2006.
92. Driscoll DM and Copeland PR. Mechanism and regulation of selenoprotein synthesis. Annu Rev Nutr 23: 11-40, 2003.
93. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF Jr. Slate EH, Fischbach LA, Marshall JR, and Clark LC. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 11: 630-639, 2002.
94. Duffield AJ, Thomson CD, Hill KE, and Williams S. An estimation of selenium requirements for New Zealanders. Am J Clin Nutr 70: 896-903, 1999.
95. Dumitrescu AM, Liao XII, Abdullah MS, Lado-Abeal J, Majed FA, Moeller LC, Boran G, Schomburg L, Weiss RE, and Refetoff S. Mutations in SECISBP2 result in abnormal thyroid hormone metabolism. Nat Genet 37: 1247-1252, 2005.
96. Dunand-Sauthier I, Walker CA, Narasimhan J, Pearce AK, Wek RC, and Humphrey TC. Stress-activated protein kinase pathway functions to support protein synthesis and translational adaptation in response to environmental stress in fission yeast. Eukaryot Cell 4: 1785-1793, 2005.
97. Esworthy RS, Aranda R, Martin MG, Doroshow JH, Binder SW, and Chu FF. Mice with combined disruption of Gpx1 and Gpx2 genes have colitis. Am J Physiol Gastrointest Liver Physiol 281: G848-G855, 2001.
98. Esworthy RS, Baker MA, and Chu FF. Expression of selenium-dependent glutathione peroxidase in human breast tumor cell lines. Cancer Res 55: 957-962, 1995.
99. Esworthy RS, Mann JR, Sam M, and Chu FF. Low glutathione peroxidase activity in Gpx1 knockout mice protects jejunum crypts from gamma-irradiation damage. Am J Physiol Gastrointest Liver Physiol 279: G426-G436, 2000.
100. Esworthy RS, Yang L, Frankel PH, Chu FF, Aranda R, Martin MG, Doroshow JH, and Binder SW. Epithelium-specific glutathione peroxidase, Gpx2, is involved in the prevention of intestinal inflammation in selenium-deficient mice: mice with combined disruption of Gpx1 and Gpx2 genes have colitis. J Nutr 135: 740-745, 2005.
101. Fagegaltier D, Hubert N, Yamada K, Mizutani T, Carbon P, and Krol A. Characterization of mSelB, a novel mammalian elongation factor for selenoprotein translation. EMBO J 19: 4796-4805, 2000.
102. Fang J, Lu J, and Holmgren A. Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity J Biol Chem 280: 25284-25290, 2005.
103. Ferguson AD, Labunskyy VM, Fomenko DE, Arac D, Chelliah Y, Amezcua CA, Rizo J, Gladyshev VN, and Deisenhofer J. NMR structures of the selenoproteins Sep15 and SelM reveal redox activity of a new thioredoxin-like family. J Biol Chem 281: 3536-3543, 2006.
104. Fernandez J, Yaman I, Mishra R, Merrick WC, Snider MD, Lamers WH, and Hatzoglou M. Internal ribosome entry site-mediated translation of a mammalian mRNA is regulated by amino acid availability. J Biol Chem 276: 12285-12291, 2001.
105. Ferreiro A, Quijano-Roy S, Pichereau C, Moghadaszadeh B, Goemans N, Bonnemann C, Jungbluth H, Straub V, Villanova M, Leroy JP, Romero NB, Martin JJ, Muntoni F, Voit T, Estournet B, Richard P, Fardeau M, and Guicheney P. Mutations of the selenoprotein N gene, which is implicated in rigid spine muscular dystrophy, cause the classical phenotype of multiminicore disease: reassessing the nosology of early-onset myopathics. Am J Hum Genet 71: 739-749, 2002.
106. Fletcher JE, Copeland PR, and Driscoll DM. Polysome distribution of phospholipid hydroperoxide glutathione peroxidase mRNA: evidence for a block in elongation at the UGA/selenocysteine codon. RNA 6: 1573-1584, 2000.
107. Fletcher JE, Copeland PR, Driscoll DM, and Krol A. The selenocysteine incorporation machinery: interactions between the SECIS RNA and the SECIS-binding protein SBP2. RNA 7: 1442-1453, 2001.
108. Flohe L, Gunzler WA, and Schock HH. Glutathione peroxidase: a selenoenzyme. FEBS Lett 32: 132-134, 1973.
109. Florian S, Wingler K, Schmehl K, Jacobasch G, Krcuzer OJ, Meyerhof W, and Brigelius-Flohe R. Cellular and subcellular localization of gastrointestinal glutathione peroxidase in normal and malignant human intestinal tissue. Free Radic: Res 35: 655-663, 2001.
110. Fomenko DE and Gladyshev VN. Identity and functions of CxxC-derived motifs. Biochemistry 42: 11214-1 1225, 2003.
111. Fomenko DE, Xing W, Adair BM, Thomas DJ, and Gladyshev VN. High-throughput identification of catalytic redox-active cysteine residues. Science 315: 387-389, 2007.
112. Foresta C, Flohe L, Garolla A, Roveri A, Ursini F, and Maiorino M. Male fertility is linked to the selenoprotein phospholipid hydroperoxide glutathione peroxidase. Biol Reprod 67: 967-971, 2002.
113. Forstrom JW, Zakowski JJ, and Tappel AL. Identification of the catalytic site of rat liver glutathione peroxidase as selenocysteine. Biochemistry 17: 2639-2644, 1978.
114. Gan L, Yang XL, Liu Q, and Xu HB. Inhibitory effects of thioredoxin reductase antisense RNA on the growth of human hepatocellular carcinoma cells. J Cell Biochem 96: 653-664, 2005.
115. Ganther HE. Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis 20: 1657-1666, 1999.
116. Gao Y, Hannan NR, Wanyonyi S, Konstantopolous N, Pagnon J, Feng HC, Jowett JB, Kim KM, Walder K, and Collier GR. Activation of the selenoprotein SEPS1 gene expression by proinflammatory cytokines in HepG2 cells. Cytokine 33: 246-251, 2006.
117. Gelpi C, Sontheimer EJ, and Rodriguez-Sanchez JL. Autoantibodies against a serine tRNA-protcin complex implicated in cotranslational selenocysteine insertion. Proc Natl Acad Sci U S A 89: 9739-9743, 1992.
118. Ghezzi P. Regulation of protein function by glutathionylation. Free Radic Res 39: 573-580, 2005.
119. Giometti CS, Liang X, Tollaksen SL, Wall DB, Lubman DM, Subbarao V, and Rao MS. Mouse liver selenium-binding protein decreased in abundance by peroxisome proliferators. Electrophoresis 21: 2162-2169, 2000.
120. Gladyshev VN, Jeang KT, and Stadtman TC. Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc Natl Acad Sci U S A 93: 6146-6151, 1996.
121. Grogan TM, Fenoglio-Prieser C, Zeheb R, Bellamy W, Frutiger Y, Vela E, Stemmerman G, Macdonald J, Richter L, Gallegos A, and Powis G. Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum Pathol 31: 475-481, 2000.
122. Gromer S and Gross JH. Methylseleninate is a substrate rather than an inhibitor of mammalian thioredoxin reductase: implications for the antitumor effects of selenium. J Biol Chem 277: 9701-9706, 2002.
123. Gross M, Oertel M, and Kohrle J. Differential selenium-dependent expression of type I 5′-deiodinase and glutathione peroxidase in the porcine epithelial kidney cell line LLC-PKI. Biochem J 306: 851-856, 1995.
124. Gu QP, Beilstein MA, Barofsky E, Ream W, and Whanger PD. Purification, characterization, and glutathione binding to selenoprotein W from monkey muscle. Arch Biochem Biophys 361: 25-33, 1999.
125. Guimaraes MJ, Peterson D, Vicari A, Cocks BG, Copeland NG, Gilbert DJ, Jenkins NA, Ferrick DA, Kastelein RA, Bazan JF, and Zlotnik A. Identification of a novel selD homolog from eukaryotes, bacteria, and archaea: is there an autoregulatory mechanism in selenocysteine metabolism? Proc Natl Acad Sci U S A 93:15086-15091, 1996.
126. Hara S, Shoji Y, Sakurai A, Yuasa K, Himeno S, and Imura N. Effects of selenium deficiency on expression of selenoproteins in bovine arterial endothelial cells. Biol Pharm Bull 24: 754-759, 2001.
127. Hashemy SI, Ungerstedt JS, Zahedi Avval F, and Holmgren A. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J Biol Chem 281: 10691-10697, 2006.
128. Hatfield D. Selenium: its molecular biology and role in human health. Norwell: Kluver Academic Publishers, 2001.
129. Hatfield D, Lee BJ, Hampton L, and Diamond AM. Selenium induces changes in the selenocysteine tRNA[Ser]Sec population in mammalian cells. Nucleic Acids Res 19: 939-943, 1991.
130. Hatfield DL, Berry MJ, and Gladyshev VN. Selenium: its molecular biology and role in human health. 2nd ed. New York: Springer Science+Business Media, 2006.
131. Hatfield DL and Gladyshev VN. How selenium has altered our understanding of the genetic code. Mol Cell Biol 22: 3565-3576, 2002.
132. Hattori H, Imai H, Furuhama K, Sato O, and Nakagawa Y. Induction of phospholipid hydroperoxide glutathione peroxidase in human polymorphonuclear neutrophils and HL60 cells stimulated with TNF-alpha. Biochem Biophys Res Commun 337: 464-473, 2005.
133. He QY, Cheung YH, Leung SY, Yuen ST, Chu KM, and Chiu JF. Diverse proteomic alterations in gastric adenocarcinoma. Proleomics 4: 3276-3287, 2004.
134. Hedley D, Pintilie M, Woo J, Nicklee T, Morrison A, Birle D, Fyles A, Milosevic M, and Hill R. Up-regulation of the redox mediators thioredoxin and apurinic/apyrimidinic excision (APE)/Ref-1 in hypoxic microregions of invasive cervical carcinomas, mapped using multispectral, wide-field fluorescence image analysis. Am. J Pathol 164: 557-565, 2004.
135. Hill KE, Lyons PR, and Burk RF. Differential regulation of rat liver selenoprotein mRNAs in selenium deficiency. Biochem Biophys Res Commun 185: 260-263, 1992.
136. Hill KE, Zhou J, McMahan WJ, Motley AK, Atkins JF, Gesteland RF, and Burk RF. Deletion of selenoprotein P alters distribution of selenium in the mouse. J Biol Chem 278: 13640-13646, 2003.
137. Hintze KJ, Wald KA, Zeng H, Jeffery EH, and Finley JW. Thioredoxin reductase in human hepatoma cells is transcriptionally regulated by sulforaphane and other electrophiles via an antioxidant response clement. J Nutr 133: 2721-2727, 2003.
138. Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, and Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci U S A 94: 3633-3638, 1997.
139. Ho YS, Magnenat JL, Bronson RT, Cao J, Gargano M, Sugawara M, and Funk CD. Mice deficient in cellular glutathione peroxidase develop normally and show no increased sensitivity to hyperoxia. J Biol Chem 272: 16644-16651, 1997.
140. Holcik M and Sonenberg N. Translational control in stress and apoptosis. Nat Rev Mol Cell Biol 6: 318-327, 2005.
141. Holmgren A. Thioredoxin. Annu Rev Biochem 54: 237-271, 1985.
142. Holmgren A. Thioredoxin and glutaredoxin systems. J Biol Chem 264: 13963-13966, 1989.
143. Holmgren A and Lyckeborg C. Enzymatic reduction of alloxan by thioredoxin and NADPH-thioredoxin reductase. Proc Natl Acad Sci U S A 77: 5149-5152, 1980.
144. Hooven LA, Vorachek WR, Bauman AB, Butler JA, Ream LW, and Whanger PD. Deletion analysis of the rodent selenoprotein W promoter. J Inorg Biochem 99: 2007-2012, 2005.
145. Hough CD, Cho KR, Zonderman AB, Schwartz DR, and Morin PJ. Coordinately up-regulated genes in ovarian cancer. Cancer Res 61: 3869-3876, 2001.
146. Howard MT, Aggarwal G, Anderson CB, Khatri S, Flanigan KM, and Atkins JF. Recoding elements located adjacent to a subset of eukaryal selenocystecine- specifying UGA codons. EMBO J 24: 1596-1607, 2005.
147. Hu Y, Benya RV, Carroll RE, and Diamond AM. Allelic loss of the gene for the GPX1 selenium-containing protein is a common event in cancer. J Nutr 135: 3021S-3024S, 2005.
148. Hu YJ and Diamond AM. Role of glutathione peroxidase 1 in breast cancer: loss of heterozygosity and allelic differences in the response to selenium. Cancer Res 63: 3347-3351, 2003.
149. Hu YJ, Dolan ME, Bae R, Yee H, Roy M, Glickman R, Kiremidjian-Schumacher L, and Diamond AM. Allelic loss at the GPx-1 locus in cancer of the head and neck. Biol Trace Elem Res 101: 97-106, 2004.
150. Hu YJ, Korotkov KV, Mehta R, Hatfield DL, Rotimi CN, Luke A, Prewitt TE, Cooper RS, Stock W, Vokes EE, Dolan ME, Gladyshev VN, and Diamond AM. Distribution and functional consequences of nucleotide polymorphisms in the 3′-untranslated region of the human Sep15 gene. Cancer Res 61: 2307-2310, 2001.
151. Huang KC, Park DC, Ng SK, Lee JY, Ni X, Ng WC, Bandera CA, Welch WR, Berkowitz RS, Mok SC, and Ng SW. Selenium binding protein 1 in ovarian cancer. Int J Cancer 118: 2433-2440, 2006.
152. Hwang DY, Cho JS, Oh JH, Shim SB, Jee SW, Lee SH, Seo SJ, Lee SK, Lee SH, and Kim YK. Differentially expressed genes in transgenic mice carrying human mutant presenilin-2 (N1411): correlation of selenoprotein M with Alzheimer's disease. Neurochem Res 30: 1009-1019, 2005.
153. Ichimura Y, Habuchi T, Tsuchiya N, Wang L, Oyama C, Sato K, Nishiyama H, Ogawa O, and Kato T. Increased risk of bladder cancer associated with a glutathione peroxidase 1 codon 198 variant. J Urol 172: 728-732, 2004.
154. Imai H, Graham DI, Masayasu H, and Macrae IM. Antioxidant ebselen reduces oxidative damage in focal cerebral ischemia. Free Radic Biol Med 34: 56-63, 2003.
155. Imai H, Hirao F, Sakamoto T, Sekine K, Mizukura Y, Saito M, Kitamoto T, Flayasaka M, Hanaoka K, and Nakagawa Y. Early embryonic lethality caused by targeted disruption of the mouse PHGPx gene. Biochem Biophys Res Commun 305: 278-286, 2003.
156. Imai H and Nakagawa Y. Biological significance of phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) in mammalian cells. Free Radic Biol Med 34: 145-169, 2003.
157. Imai H, Saito M, Kirai N, Hasegawa J, Konishi K, Hattori H, Nishimura M, Naito S, and Nakagawa Y. Identification of the positive regulatory and distinct core regions of promoters, and transcriptional regulation in three types of mouse phospholipid hydroperoxide glutathione peroxidase. J Biochem (Tokyo) 140: 573-590, 2006.
158. Ip C and Ganther HE. Comparison of selenium and sulfur analogs in cancer prevention. Carcinogenesis 13: 1167-1170, 1992.
159. Ip C, Thompson HJ, Zhu Z, and Ganther HE. In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 60: 2882-2886, 2000.
160. Jakupoglu C, Przemeck GK, Schneider M, Moreno SG, Mayr N, Hatzopoulos AK, de Angelis MH, Wurst W, Bornkamm GW, Brielmeier M, and Conrad M. Cytoplasmic thioredoxin reductase is essential for embryogenesis but dispensable for cardiac development. Mol Cell Biol 25: 1980-1988, 2005.
161. Jameson RR, Carlson BA, Butz M, Esser K, Hatfield DL, and Diamond AM. Selenium influences the turnover of selenocysteine tRNA([Ser]Sec) in Chinese hamster ovary cells. J Nutr 132: 1830-1835, 2002.
162. Jameson RR and Diamond AM. A regulatory role for Sec tRNA[Ser]Sec in selenoprotein synthesis. RNA 10: 1142-1152, 2004.
163. Jeong D, Kim TS, Chung YW, Lee BJ, and Kim IY. Selenoprotein W is a glutathione-depcndent antioxidant in vivo. FEBS Lett 517: 225-228, 2002.
164. Johansson L, Gafvelin G, and Arner ES. Selenocysteine in proteins: properties and biotechnological use. Biochim Biophys Acta 1726: 1-13, 2005.
165. Jonnalagadda SB and Rao PV. Toxicity, bioavailability and metal speciation. Comp Biochem Physiol C 106: 585-595, 1993.
166. Kahlos K, Soini Y, Saily M, Koistinen P, Kakko S, Paakko P, Holmgren A, and Kinnula VL. Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma. Int J Cancer 95: 198-204, 2001.
167. Kakolyris S, Giatromanolaki A, Koukourakis M, Powis G, Souglakos J, Sivridis E, Georgoulias V, Gatter KC, and Harris AL. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 7: 3087-3091, 2001.
168. Karimpour S, Lou J, Lin LL, Rene LM, Lagunas L, Ma X, Karra S, Bradbury CM, Markovina S, Goswami PC, Spitz DR, Hirota K, Kalvakolanu DV, Yodoi J, and Gius D. Thioredoxin reductase regulates AP-1 activity as well as thioredoxin nuclear localization via active cysteines in response to ionizing radiation. Oncogene 21: 6317-6327, 2002.
169. Kawahara N, Tanaka T, Yokomizo A, Nanri H, Ono M, Wada M, Kohno K, Takenaka K, Sugimachi K, and Kuwano M. Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res 56: 5330-5333, 1996.
170. Kester MH, Kuiper GG, Versteeg R, and Visser TJ. Regulation of type III iodothyronine deiodinase expression in human cell lines. Endocrinology 147: 5845-5854, 2006.
171. Kim BW, Daniels GH, Harrison BJ, Price A, Harney JW, Larsen PR, and Weetman AP. Overexpression of type 2 iodothyronine deiodinase in follicular carcinoma as a cause of low circulating free thyroxine levels. J Clin Endocrinol Melab 88: 594-598, 2003.
172. Kim H, Kang HJ, You KT, Kim SH, Lee KY, Kim TI, Kim C, Song SY, Kim HJ, and Lee C. Suppression of human selenium-binding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. Proteomics 6: 3466-3476, 2006.
173. Kim HY and Gladyshev VN. Methionine sulfoxide reduction in mammals: characterization of methionine-R-sulfoxide reductases. Mol Biol Cell 15: 1055-1064, 2004.
174. Kim MR, Chang HS, Kim BH, Kim S, Baek SH, Kim JH, Lee SR, and Kim JR. Involvements of mitochondrial thioredoxin reductase (TrxR2) in cell proliferation. Biochem Biophys Res Commun 304: 119-124, 2003.
175. Kinzy SA, Caban K, and Copeland PR. Characterization of the SECIS binding protein 2 complex required for the co-translational insertion of selenocysteine in mammals. Nucleic Acids Res 33: 5172-5180, 2005.
176. Kocdor H, Cehreli R, Kocdor MA, Sis B, Yilmaz O, Canda T, Demirkan B, Resmi H, Alakavuklar M, and Harmancioglu O. Toxicity induced by the chemical carcinogen 7,12-dimethyl-benz[a]anthracene and the protective effects of selenium in Wistar rats. J Toxicol Environ Health A 68: 693-701, 2005.
177. Koenig RJ. Regulation of type 1 iodothyronine deiodinase in health and disease. Thyroid 15: 835-840, 2005.
178. Kohrle J, Jakob F, Contempre B, and Dumont JE. Selenium, the thyroid, and the endocrine system. Endocr Rev 26: 944-984, 2005.
179. Korotkov KV, Kumaraswamy E, Zhou Y, Hatfield DL, and Gladyshev VN. Association between the 15-kDa selenoprotein and UDP-glucose:glycoprotein glucosyltransferase in the endoplasmic reticulum of mammalian cells. J Biol Chem 276: 15330-15336, 2001.
180. Korotkov KV, Novoselov SV, Hatfield DL, and Gladyshev VN. Mammalian selenoprotein in which selenocysteine (Sec) incorporation is supported by a new form of Sec insertion sequence element. Mol Cell Biol 22: 1402-1411, 2002.
181. Kote-Jarai Z, Durocher F, Edwards SM, Hamoudi R, Jackson RA, Ardern-Jones A, Murkin A, Dearnaley DP, Kirby R, Houlston R, Easton DF, and Eeles R. Association between the GCG polymorphism of the selenium dependent GPX1 gene and the risk of young onset prostate cancer. Prostate Cancer Prostatic Dis 5: 189-192, 2002.
182. Kovacic P and Jacintho JD. Mechanisms of carcinogenesis: focus on oxidative stress and electron transfer. Curr Med Chem 8: 773-796, 2001.
183. Krol A. Evolutionary different RNA motifs and RNA-protein complexes to achieve selenoprotein synthesis. Biochimie 84: 765-774, 2002.
184. Kryukov GV, Castellano S, Novoselov SV, Lobanov AV, Zehtab O, Guigo R, and Gladyshev VN. Characterization of mammalian selenoproteomes. Science 300: 1439-1443, 2003.
185. Kryukov GV and Gladyshev VN. The prokaryotic selenoproteome. EMBO Rep 5: 538-543, 2004.
186. Kryukov GV, Kumar RA, Koc A, Sun Z, and Gladyshev VN. Selenoprotein R is a zinc-containing stereo-specific methionine sulfoxide reductase. Proc Natl Acad Sci U S A 99: 4245-4250, 2002.
187. Kuge S, Arita M, Murayama A, Maeta K, Izawa S, Inoue Y, and Nomoto A. Regulation of the yeast Yap1p nuclear export signal is mediated by redox signal-induced reversible disulfide bond formation. Mol Cell Biol 21: 6139-6150, 2001.
188. Kuge S, Jones N, and Nomoto A. Regulation of yAP-1 nuclear localization in response to oxidative stress. EMBO J 16: 1710-1720, 1997.
189. Kumar S, Bjornstedt M, and Holmgren A. Selenite is a substrate for calf thymus thioredoxin reductase and thioredoxin and elicits a large non-stoichiometric oxidation of NADPH in the presence of oxygen. Eur J Biochem 207: 435-439, 1992.
190. Kumaraswamy E, Carlson BA, Morgan F, Miyoshi K, Robinson GW, Su D, Wang S, Southon E, Tessarollo L, Lee BJ, Gladyshev VN, Hennighausen L, and Hatfield DL. Selective removal of the selenocysteine tRNA [Ser]Sec gene (Trsp) in mouse mammary epithelium. Mol Cell Biol 23: 1477-1488, 2003.
191. Kumaraswamy E, Malykh A, Korotkov KV, Kozyavkin S, Hu Y, Kwon SY, Moustafa ME, Carlson BA, Berry MJ, Lee BJ, Hatfield DL, Diamond AM, and Gladyshev VN. Structure-expression relationships of the 15-kDa selenoprotein gene; possible role of the protein in cancer etiology. J Biol Chem 275: 35540-35547, 2000.
192. Labunskyy VM, Ferguson AD, Fomenko DE, Chelliah Y, Hatfield DL, and Gladyshev VN. A novel cysteine-rich domain of Sep15 mediates the interaction with UDP-glucose:glycoprotein glucosyltransferase. J Biol Chem 280: 37839-37845, 2005.
193. Lanfear J, Fleming J, Walker M, and Harrison P. Different patterns of regulation of the genes encoding the closely related 56 kDa selenium- and acetaminophen-binding proteins in normal tissues and during carcinogenesis. Carcinogenesis 14: 335-340, 1993.
194. Lee BJ, Worland PJ, Davis JN, Stadtman TC, and Hatfield DL. Identification of a selenocysteyl-tRNA(Ser) in mammalian cells that recognizes the nonsense codon, UGA. J Biol Chem 264: 9724-9727, 1989.
195. Lee BJ, Worland PJ, Davis JN, Stadtman TC, and Hatfield DL. Identification of a selenocysteyl-tRNA(Ser) in mammalian cells that recognizes the nonsense codon, UGA. J Biol Chem 264: 9724-9727, 1989.
196. Lee O,I, Schneider-Stock R, McChesney PA, Kuester D, Roessner A, Vieth M, Moskaluk CA, and El-Rifai W. Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis. Neoplasia 7: 854-861, 2005.
197. Lee SR, Kim JR, Kwon KS, Yoon HW, Levine RL, Ginsburg A, and Rhee SG. Molecular cloning and characterization of a mitochondrial selenocysteine- containing thioredoxin reductase from rat liver. J Biol Chem 274: 4722-4734, 1999.
198. Lei XG and Cheng WH. New roles for an old selenoenzyme: evidence from glutathione peroxidase-1 null and overexpressing mice. J Nutr 135: 2295-2298, 2005.
199. Leinfelder W, Stadtman TC, and Bock A. Occurrence in vivo of selenocysteyl-tRNA(SERUCA) in Escherichia coli: effect of sel mutations. J Biol Chem 264: 9720-9723, 1989.
200. Leinfelder W, Zehelein E, Mandrand-Berthelot MA, and Bock A. Gene for a novel tRNA species that accepts L-serine and cotranslationally inserts selenocysteine. Nature 331: 723-725, 1988.
201. Leonard JL and Rosenberg IN. Thyroxine 5′-deiodinase activity of rat kidney: observations on activation by thiols and inhibition by propylthiouracil. Endocrinology 103: 2137-2144, 1978.
202. Lescure A, Allmang C, Yamada K, Carbon P, and Krol A. cDNA cloning, expression pattern and RNA binding analysis of human selenocysteine insertion sequence (SECIS) binding protein 2. Gene 291: 279-285, 2002.
203. Levander OA and Beck MA. Interacting nutritional and infectious etiologies of Keshan disease: insights from Coxsackie virus B-induced myocarditis in mice deficient in selenium or vitamin E. Biol Trace Elem Res 56: 5-21, 1997.
204. Li GS, Wang F, Kang D, and Li C. Keshan disease: an endemic cardiomyopathy in China. Hum Pathol 16: 602-609, 1985.
205. Li LS, Kim H, Rhee H, Kim SH, Shin DM, Chung KY, Park KS, Paik YK, and Chang J. Proteomic analysis distinguishes basaloid carcinoma as a distinct subtype of nonsmall cell lung carcinoma. Proteomics 4: 3394-3400, 2004.
206. Lin YM, Furukawa Y, Tsunoda T, Yue CT, Yang KC, and Nakamura Y. Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. Oncogene 21: 4120-4128, 2002.
207. Linke K and Jakob U. Not every disulfide lasts forever: disulfide bond formation as a redox switch. Antioxid Redox Signal 5: 425-434, 2003.
208. Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM Jr. Kristal AR, Santella RM, Probstfield JL, Moinpour CM, Albanes D, Taylor PR, Minasian LM, Hoque A, Thomas SM, Crowley JJ, Gaziano JM, Stanford JL, Cook ED, Fleshner NE, Lieber MM, Walther PJ, Khuri FR, Karp DD, Schwartz GG, Ford LG, and Coltman CA Jr. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 97: 94-102, 2005.
209. Lodygin D, Epanchintsev A, Menssen A, Diebold J, and Hermeking II. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 65: 4218-4227, 2005.
210. Loflin J, Lopez N, Whanger PD, and Kioussi C. Selenoprotein W during development and oxidative stress. J Inorg Biochem 100: 1679-1684, 2006.
211. Lu C, Qiu F, Zhou H, Peng Y, Hao W, Xu J, Yuan J, Wang S, Qiang B, Xu C, and Peng X. Identification and characterization of selenoprotein K: an antioxidant in cardiomyocytes. FEBS Lett 580: 5189-5197, 2006.
212. Lu J, Papp LV, Fang J, Rodriguez-Nieto S, Zhivotovsky B, and Holmgren A. Inhibition of mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Res 66: 4410-4418, 2006.
213. Lundstrom-Ljung J, Birnbach U, Rupp K, Soling HD, and Holmgren A. Two resident ER-proteins, CaBP1 and CaBP2. with thioredoxin domains, are substrates for thioredoxin reductase: comparison with protein disulfide isomerase. FEBS Lett 357: 305-308, 1995.
214. Lundstrom J and Holmgren A. Protein disulfide-isomerase is a substrate for thioredoxin reductase and has thioredoxin-like activity. J Biol Chem 265: 9114-9120, 1990.
215. Luthman M and Holmgren A. Glutaredoxin from calf thymus: purification to homogeneity. J Biol Chem 257: 6686-6690, 1982.
216. Luthman M and Holmgren A. Rat liver thioredoxin and thioredoxin reductase: purification and characterization. Biochemistry 21: 6628-6633, 1982.
217. Ma S, Hill KE, Caprioli RM, and Burk RF. Mass spectrometric characterization of full-length rat selenoprotein P and three isoforms shortened at the C terminus: evidence that three UGA codons in the mRNA open reading frame have alternative functions of specifying selenocysteine insertion or translation termination. J Biol Chem 277: 12749-12754, 2002.
218. Maia AL, Kim BW, Huang SA, Harney JW, and Larsen PR. Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J Clin Invest 115: 2524-2533, 2005.
219. Maiorino M, Scapin M, Ursini F, Biasolo M, Bosello V, and Flohe L. Distinct promoters determine alternative transcription of gpx-4 into phospholipid-hydroperoxide glutathione peroxidase variants. J Biol Chem 278: 34286-34290, 2003.
220. Maquat LE. Evidence that selenium deficiency results in the cytoplasmic decay of GPx1 mRNA dependent on pre-mRNA splicing proteins bound to the mRNA exon-exon junction. Biofactors 14: 37-42, 2001.
221. Marchetti MA, Pizarro GO, Sagher D, Deamicis C, Brot N, Hejtmancik JF, Weissbach H, and Kantorow M. Methionine sulfoxide reductases B1, B2, and B3 are present in the human lens and confer oxidative stress resistance to lens cells. Invest Ophthalmol Vis Sci 46: 2107-2112, 2005.
222. Marshall JR, Sakr W, Wood D, Berry D, Tangen C, Parker F, Thompson I, Lippman SM, Lieberman R, Alberts D, Jarrard D, Coltman C, Greenwald P, Minasian L, and Crawford ED. Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 15: 1479-1484, 2006.
223. Martin GW 3rd and Berry MJ. Selenocysteine codons decrease polysome association on endogenous selenoprotein mRNAs. Genes Cells 6: 121-129, 2001.
224. Matsui M, Oshima M, Oshima H, Takaku K, Maruyama T, Yodoi J, and Taketo MM. Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene. Dev Biol 178: 179-185, 1996.
225. Matsutani Y, Yamauchi A, Takahashi R, Ueno M, Yoshikawa K, Honda K, Nakamura H, Kato H, Kodama H, Inamoto T, Yodoi J, and Yamaoka Y. Inverse correlation of thioredoxin expression with estrogen receptor- and p53-dependent tumor growth in breast cancer tissues. Clin Cancer Res 7: 3430-3436, 2001.
226. Mau BL and Powis G. Inhibition of cellular thioredoxin reductase by diaziquone and doxorubicin: relationship to the inhibition of cell-proliferation and decreased ribonucleotide reductase-activity. Biochem Pharmacol 43: 1621-1626, 1992.
227. May JM, Cobb CE, Mendiratta S, Hill KE, and Burk RF. Reduction of the ascorbyl free radical to ascorbate by thioredoxin reductase. J Biol Chem 273: 23039-23045, 1998.
228. Miranda-Vizuete A, Damdimopoulos AE, Pedrajas JR, Gustafsson JA, and Spyrou G. Human mitochondrial thioredoxin reductase cDNA cloning, expression and genomic organization. Eur J Biochem 261: 405-412, 1999
229. Miranda-Vizuete A and Spyrou G. Genomic organization and identification of a novel alternative splicing variant of mouse mitochondrial thioredoxin reductase (TrxR2) gene. Mol Cells 13: 488-492, 2002.
230. Moghadaszadeh B, Petit N, Jaillard C, Brockington M, Roy SQ, Merlini L, Romero N, Estournet B, Desguerre I, Chaigne D, Muntoni F, Topaloglu H, and Guicheney P. Mutations in SEPN1 cause congenital muscular dystrophy with spinal rigidity and restrictive respiratory syndrome. Nat Genet 29: 17-18, 2001.
231. Moore T, Zhang Y, Fenley MO, and Li H. Molecular basis of box C/D RNA-protcin interactions: cocrystal structure of archaeal L7Ae and a box C/D RNA. Structure 12: 807-818, 2004.
232. Moriarty PM, Reddy CC, and Maquat LE. Selenium deficiency reduces the abundance of mRNA for Se-dependent glutathione peroxidase 1 by a UGA-dependent mechanism likely to be nonsense codon-mediated decay of cytoplasmic mRNA. Mol Cell Biol 18: 2932-2939, 1998.
233. Mork H, al-Taie OH, Bahr K, Zierer A, Beck C, Scheurlen M, Jakob F, and Kohrle J. Inverse mRNA expression of the selenocysteine-containing proteins GI-GPx and SeP in colorectal adenomas compared with adjacent normal mucosa. Nutr Cancer 31: 108-116, 2000.
234. Mork H, Scheurlen M, Al-Taie O, Zierer A, Kraus M, Schottker K, Jakob F, and Kohrle J. Glutathione peroxidase isoforms as part of the local antioxidative defense system in normal and Barrett's esophagus. Int J Cancer 105: 300-304, 2003.
235. Moscow JA, Schmidt L, Ingram DT, Gnarra J, Johnson B, and Cowan KH. Loss of heterozygosity of the human cytosolic glutathione peroxidase 1 gene in lung cancer. Carcinogenesis 15: 2769-2773, 1994.
236. Moustafa ME, Carlson BA, El-Saadani MA, Kryukov GV, Sun QA, Harney JW, Hill KE, Combs GF, Feigenbaum L, Mansur DB, Burk RF, Berry MJ, Diamond AM, Lee BJ, Gladyshev VN, Hatfield DL, and Kandeel KM. Selective inhibition of selenocysteine tRNA maturation and selenoprotein synthesis in transgenic mice expressing isopentenyladenosine-deficient selenocysteine tRNA: overproduction of selenocysteine tRNA in Chinese hamster ovary cells following transfection of the mouse tRNA[Ser]Sec gene. Mol Cell Biol 21: 3840-3852, 2001.
237. Midler A, Cadenas E, Graf P, and Sies H. A novel biologically active seleno-organic compound, 1. Glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ 51 (Ebselen). Biochem Pharmacol 33: 3235-3239, 1984.
238. Murray JI, Whitfield ML, Trinklein ND, Myers RM, Brown PO, and Botstein D. Diverse and specific gene expression responses to stresses in cultured human cells. Mol Biol Cell 15: 2361-2374, 2004.
239. Mushak P. Potential impact of acid precipitation on arsenic and selenium. Environ Health Perspeet 63: 105-1 13, 1985.
240. Nakahara R, Tsunekawa K, Yabe S, Nara M, Seki K, Kasahara T, Ogiwara T, Nishino M, Kobayashi I, and Murakami M. Association of antipituitary antibody and type 2 iodothyronine deiodinase antibody in patients with autoimmune thyroid disease. Endocr J 52: 691-699, 2005.
241. Nalvarte I, Damdimopoulos AE, and Spyrou G. Human mitochondrial thioredoxin reductase reduces cytochrome c and confers resistance to complex 111 inhibition. Free Radic Biol Med 36: 1270-1278, 2004.
242. Nasr MA, Fedele MJ, Esser K, and Diamond AM. GPx-1 modulates Akt and P70S6K phosphorylation and Gadd45 levels in MCF-7 cells. Free Radic Biol Med 37: 187-195, 2004.
243. Nevins TA, Harder ZM, Korneluk RG, and Holcik M. Distinct regulation of internal ribosome entry site-mediated translation following cellular stress is mediated by apoptotic fragments of eIF4G translation initiation factor family members eIF4GI and p97/DAP5/NAT1. J Biol Chem 278: 3572-3579, 2003.
244. Nikitovic D and Holmgren A. S-nitrosoglutathione is cleaved by the thioredoxin system with liberation of glutathione and redox regulating nitric oxide. J Biol Chem 271: 19180-19185, 1996.
245. Nonn L, Williams RR, Erickson RP and Powis G. The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice. Mol Cell Biol 23: 916-922, 2003.
246. Novoselov SV and Gladyshev VN. Non-animal origin of animal thioredoxin reductases: implications for selenocysteine evolution and evolution of protein function through carboxy-terminal extensions. Protein Sci 12: 372-378, 2003.
247. Ogawa A, Yoshimoto T, Kikuchi H, Sano K, Saito I, Yamaguchi T, and Yasuhara H. Ebselen in acute middle cerebral artery occlusion: a placebo-controlled, double-blind clinical trial. Cerebrovasc Dis 9: 112-118, 1999.
248. Olson GE, Winfrey VP, Hill KE, and Burk RF. Sequential development of flagellar defects in spermatids and epididymal spermatozoa of selenium-deficient rats. Reproduction 127: 335-342, 2004.
249. Osawa S, Jukes TH, Watanabe K, and Muto A. Recent evidence for evolution of the genetic code. Microbiol Rev 56: 229-264, 1992.
250. Papp LV Lu J, Striebel F, Kennedy D, Holmgren A, and Khanna KK. The redox state of SECIS binding protein 2 controls its localization and selenocysteine incorporation function. Mol Cell Biol 26: 4895-4910, 2006.
251. Park JY, Seong JK, and Paik YK. Proteomic analysis of diet-induced hypercholesterolemic mice. Proteomics 4: 514-523, 2004.
252. Persson-Moschos ME, Stavenow L, Akesson B, and Lindgarde F. Selenoprotein P in plasma in relation to cancer morbidity in middle-aged Swedish men. Nutr Cancer 36: 19-26, 2000.
253. Peters MM, Hill KE, Burk RF, and Weeber EJ. Altered hippocampus synaptic function in selenoprotein P deficient mice. Mol Neurodegener 1: 12, 2006.
254. Petit N, Lescure A, Rederstorff M, Krol A, Moghadaszadeh B, Wewer UM, and Guicheney P. Selenoprotein N: an endoplasmic reticulum glycoprotein with an early developmental expression pattern. Hum Mol Genet 12: 1045-1053, 2003.
255. Porat A, Sagiv Y, and Elazar Z. A 56-kDa selenium-binding protein participates in intra-Golgi protein transport. J Biol Chem 275: 14457-14465, 2000.
256. Powis G, Mustacich D, and Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 29: 312-322, 2000.
257. Pumford NR, Martin BM, and Hinson JA. A metabolite of acetaminophen covalently binds to the 56 kDa selenium binding protein. Biochem Biophys Res Commnn 182: 1348-1355, 1992.
258. Raffel J, Bhattacharyya AK, Galecgos A, Cui H, Einspahr JG, Alberts DS, and Powis G. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med 142: 46-51, 2003.
259. Rafferty TS, Walker C, Hunter JA, Beckett GJ, and McKenzie RC. Inhibition of ultraviolet B radiation-induced interleukin 10 expression in murine keratinocytes by selenium compounds. Br J Dermatol 146: 485-489, 2002.
260. Rand JD and Grant CM. The thioredoxin system protects ribosomes against stress-induced aggregation. Mol Biol Cell 17: 387-401, 2006.
261. Ratnasinghe D, Tangrea JA, Andersen MR, Barrett MJ, Virtamo J, Taylor PR, and Albanes D. Glutathione peroxidase codon 198 polymorphism variant increases lung cancer risk. Cancer Res 60: 6381-6383, 2000.
262. Rayman MP. The importance of selenium to human health. Lancet 356: 233-241, 2000.
263. Rayman MP. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc 64: 527-542, 2005.
264. Read R, Bellew T, Yang JG, Hill KE, Palmer IS, and Burk RF. Selenium and amino acid composition of selenoprotein P: the major selenoprotein in rat scrum. J Biol Chem 265: 17899-17905, 1990.
265. Rederstorff M, Krol A, and Lescure A. Understanding the importance of selenium and selenoproteins in muscle function. Cell Mol Life Sci 63: 52-59, 2006.
266. Reeves WC, Marcuard SP, Willis SE, and Movahed A. Reversible cardiomyopathy due to selenium deficiency. JPEN J Parenter Enteral Nutr 13: 663-665, 1989.
267. Reid ME, Duffield-Lillico AJ, Garland L, Turnbull BW, Clark LC, and Marshall JR. Selenium supplementation and lung cancer incidence: an update of the nutritional prevention of cancer trial. Cancer Epidemiol Biomark Prev 11: 1285-1291, 2002.
268. Rhee SG, Chae HZ, and Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med 38: 1543-1552, 2005.
269. Riese C, Michaelis M, Mentrup B, Gotz F, Kohrle J, Schweizer U, and Schomburg L. Selenium-dependent pre- and posttranscriptional mechanisms are responsible for sexual dimorphic expression of selenoproteins in murine tissues. Endocrinology 147: 5883-5892, 2006.
270. Rundlof AK and Arner ES. Regulation of the mammalian selenoprotein thioredoxin reductase 1 in relation to cellular phenotype, growth, and signaling events. Antioxid Redox Signal 6: 41-52, 2004.
271. Rundlof AK, Carlsten M, Giacobini MM, and Arner ES. Prominent expression of the selenoprotein thioredoxin reductase in the medullary rays of the rat kidney and thioredoxin reductase mRNA variants differing at the 5′untranslated region. Biochem J 347(Pt 3): 661-668, 2000.
272. Sandalova T, Zhong L, Lindqvist Y, Holmgren A, and Schneider G. Three-dimensional structure of a mammalian thioredoxin reductase: implications for mechanism and evolution of a selenocysteine-dependent enzyme. Proc Natl Acad Sci U S A 98: 9533-9538, 2001.
273. Sasakura C and Suzuki KT. Biological interaction between transition metals (Ag, Cd and Hg). selenide/sulfide and selenoprotein P. J Inorg Biochem 71: 159-162, 1998.
274. Schewe T. Molecular actions of ebselen: an antiinflammatory antioxidant. Gen Pharmacol 26: 1153-1169, 1995.
275. Schomburg L, Riese C, Michaclis M, Griebert E, Klein MO, Sapin R, Schweizer U, Kohrle J, Valentine WM, Hill KE, Austin LM, Valentine HL, Goldowitz D, and Burk RF. Synthesis and metabolism of thyroid hormones is preferentially maintained in selenium-deficient transgenic mice: brainstem axonal degeneration in mice with deletion of selenoprotein p. Endocrinology 147: 1306-1313, 2006.
276. Schomburg L, Schweizer U, Holtmann B, Flohe L, Sendtner M, and Kohrle J. Gene disruption discloses role of selenoprotein P in selenium delivery to target tissues. Biochem J 370: 397-402, 2003.
277. Schomburg L, Schweizer U, and Kohrle J. Selenium and selenoproteins in mammals: extraordinary, essential, enigmatic. Cell Mol Life Sci 61:1988-1995, 2004.
278. Schweizer U and Schomburg L. New insights into the physiological actions of selenoproteins from genetically modified mice. IUBMB Life 57: 737-744, 2005.
279. Schweizer U, Streckfuss F, Pelt P, Carlson BA, Hatfield DL, Kohrle J, and Schomburg L. Hepatically derived selenoprotein P is a key factor for kidney but not for brain selenium supply. Biochem J 386: 221-226, 2005.
280. Screwko MM, Popa C, Dahler AL, Smith L, Strutton GM, Coman W, Dicker AJ, and Saunders NA. Alterations in gene expression and activity during squamous cell carcinoma development. Cancer Res 62: 3759-3765, 2002.
281. Shao L, Diccianni MB, Tanaka T, Gribi R, Yu AL, Pullen JD, Camitta BM, and Yu J. Thioredoxin expression in primary T-cell acute lymphoblastic leukemia and its therapeutic implication. Cancer Res 61: 7333-7338, 2001.
282. Sies H. Biochemistry of oxidative stress. Angew Chem Int Ed 25: 1058-1071, 1976.
283. Sies H and Masumoto H. Ebselen as a glutathione peroxidase mimic and as a scavenger of peroxynitritc. Adv Pharmacol 38: 229-246, 1997.
284. Small-Howard A, Morozova N, Stoytcheva Z, Forry EP, Mansell JB, Harney JW, Carlson BA, Xu XM, Hatfield DL, and Berry MJ, Supramolecular complexes mediate selenocysteine incorporation in vivo. Mol Cell Biol 26: 2337-2346, 2006.
285. Small-Howard AL and Berry MJ. Unique features of selenocysteine incorporation function within the context of general eukaryotic translational processes. Biochem Soc Trans 33: 1493-1497, 2005.
286. Soini Y, Kahlos K, Napankangas U, Kaarteenaho-Wiik R, Saily M, Koistinen P, Paaakko P Holmgren A, and Kinnula VL. Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin Cancer Res 7: 1750-1757, 2001.
287. St Germain DL, Hernandez A, Schneider MJ, and Galton VA. Insights into the role of deiodinases from studies of genetically modified animals. Thyroid 15: 905-916, 2005.
288. Stadtman ER. Protein oxidation and aging. Free Radic Res 40: 1250-1258, 2006.
289. Stadtman TC. Selenocysteine. Annu Rev Biochem 65: 83-100, 1996.
290. Steinbrenner H, Alili L, Bilgic E, Sies H, and Brenneisen P. Involvement of selenoprotein P in protection of human astrocytes from oxidative damage. Free Radic Biol Med 40: 1513-1523, 2006.
291. Steinbrenner H, Bilgic E, Alili L, Sies H, and Brenneisen P. Selenoprotein P protects endothelial cells from oxidative damage by stimulation of glutathione peroxidase expression and activity. Free Radic Res 40: 936-943, 2006.
292. Stoytcheva Z, Tujebajeva RM, Harney JW, and Berry MJ. Efficient incorporation of multiple selenocysteines involves an inefficient decoding step serving as a potential translational checkpoint and ribosome bottleneck. Mol Cell Biol 26: 9177-84, 2006.
293. Stratton MS, Reid ME, Schwartzberg G, Minter FE, Monroe BK, Alberts DS, Marshall JR, and Ahmann FR. Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma: study design and baseline characteristics of the "Watchful Waiting" Study. Anticancer Drugs 14: 595-600, 2003.
294. Stratton MS, Reid ME, Schwartzberg G, Minter FE, Monroe BK, Alberts DS, Marshall JR, and Ahmann FR. Selenium and prevention of prostate cancer in high-risk men: the Negative Biopsy Study. Anticancer Drugs 14: 589-594, 2003.
295. Sun QA, Kirnarsky L, Sherman S, and Gladyshev VN. Selenoprotein oxidoreductase with specificity for thioredoxin and glutathione systems. Proc Natl Acad Sci U S A 98: 3673-3678, 2001.
296. Sun QA, Wu Y, Zappacosta F, Jeang KT, Lee BJ, Hatfield DL, and Gladyshev VN. Redox regulation of cell signaling by selenocysteine in mammalian thioredoxin reductases. J Biol Chem 274:24522-24530, 1999.
297. Sun QA, Zappacosta F, Factor VM, Wirth PJ, Hatfield DL, and Gladyshev VN. Heterogeneity within animal thioredoxin reductases: evidence for alternative first exon splicing. J Biol Chem 276:3106-3114, 2001.
298. Surai P. Selenium in Nutrition and Health. Nottingham: Nottingham University Press, 2006.
299. Takahashi K, Akasaka M, Yamamoto Y, Kobayashi C, Mizoguchi J, and Koyama J. Primary structure of human plasma glutathione peroxidase deduced from cDNA sequences. J Biochem (Tokyo) 108: 145-148, 1990.
300. Takebe G, Yarimizu J, Saito Y, Hayashi T, Nakamura H, Yodoi J, Nagasawa S, and Takahashi K. A comparative study on the hydroperoxide and thiol specificity of the glutathione peroxidase family and selenoprotein P. J Biol Chem 277: 41254-41258, 2002.
301. Tamura T and Stadtman TC. A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity. Proc Natl Acad Sci U S A 93: 1006-1011, 1996.
302. Tamura T, Yamamoto S, Takahata M, Sakaguchi H, Tanaka H, Stadtman TC, and Inagaki K. Selenophosphatc synthetase genes from lung adenocarcinoma cells: Sps1 for recycling L-selenocysteine and Sps2 for selenite assimilation. Proc Natl Acad Sci U S A 101: 16162-16167, 2004.
303. Tanaka T, Kondo S, Iwasa Y, Hiai H, and Toyokuni S. Expression of stress-response and cell proliferation genes in renal cell carcinoma induced by oxidative stress. Am J Pathol 156: 2149-2157, 2000.
304. Tanito M, Masutani H, Kim YC, Nishikawa M, Ohira A, Yodoi J, Hintze KJ, Wald KA, Zeng H, Jeffery EH, and Finley JW. Sulforaphane induces thioredoxin through the antioxidant-responsive element and attenuates retinal light damage in mice: thioredoxin reductase in human hepatoma cells is transcriptionally regulated by sulforaphane and other electrophiles via an antioxidant response element. Invest Ophthalmol Vis Sci 46: 979-987, 2005.
305. Terry N, Zayed AM, De Souza MP, and Tarun AS. Selenium in higher plants. Annu Rev Plant Phvsiol Plant Mol Biol 51: 401-432, 2000.
306. Thisse C, Degrave A, Kryukov GV, Gladyshev VN, Obrecht-Pflumio S, Krol A, Thisse B, and Lescure A. Spatial and temporal expression patterns of selenoprotein genes during embryogenesis in zebrafish. Gene Expr Patterns 3: 525-532, 2003.
307. Thomas JP and Girotti AW. Photooxidation of cell membranes in the presence of hematoporphyrin derivative: reactivity of phospholipid and cholesterol hydroperoxides with glutathione peroxidase. Biochim Biophvs Acta 962: 297-307, 1988.
308. Thomson CD, Robinson MF, Butler JA, and Whanger PD. Long-term supplementation with selenate and selenomethionine: selenium and glutathione peroxidase (EC 1.11.1.9) in blood components of New Zealand women. Br J Nutr 69: 577-588, 1993.
309. Toyoda N, Zavacki AM, Maia AL, Harney JW, and Larsen PR. A novel retinoid X receptor-independent thyroid hormone response element is present in the human type 1 deiodinase gene. Mol Cell Biol 15: 5100-5112, 1995.
310. Traulsen H, Steinbrenner H, Buchczyk DP, Klotz LO, and Sies H. Selenoprotein P protects low-density lipoprotein against oxidation. Free Radic Res 38: 123-128, 2004.
311. Tujebajeva RM, Copeland PR, Xu XM, Carlson BA, Harney JW, Driscoll DM, Hatfield DL, and Berry MJ. Decoding apparatus for eukaryotic selenocysteine insertion. EMBO Rep 1: 158-163, 2000.
312. Turunen N, Karihtala P, Mantyniemi A, Sormunen R, Holmgren A, Kinnula VL, and Soini Y. Thioredoxin is associated with proliferation, p53 expression and negative estrogen and progesterone receptor status in breast carcinoma. APMIS 112: 123-132, 2004.
313. Ursini F, Heim S, Kiess M, Maiorino M, Roveri A, Wissing J, and Flohe L. Dual function of the selenoprotein PHGPx during sperm maturation. Science 285: 1393-1396, 1999.
314. Utomo A, Jiang X, Furuta S, Yun J, Levin DS, Wang YC, Desai KV, Green JE, Chen PL, and Lee WH. Identification of a novel putative non-selenocysteine containing phospholipid hydroperoxide glutathione peroxidase (NPGPx) essential for alleviating oxidative stress generated from polyunsaturated fatty acids in breast cancer cells. J Biol Chem 279: 43522-43529, 2004.
315. Valentine WM, Hill KE, Austin LM, Valentine HL, Goldowitz D, and Burk RF. Brainstem axonal degeneration in mice with deletion of selenoprotein p. Toxicol Pathol 33: 570-576, 2005.
316. Vanderpas JB, Contempre B, Duale NL, Goossens W, Bebe N, Thorpe R, Ntambue K, Dumont J, Thilly CH, and Diplock AT. Iodine and selenium deficiency associated with cretinism in northern Zaire. Am J Clin Nutr 52: 1087-1093, 1990.
317. Vendeland SC, Beilstein MA, Chen CL, Jensen ON, Barofsky E, and Whanger PD. Purification and properties of selenoprotein W from rat muscle. J Biol Chem 268: 17103-17107, 1993.
318. Vernet P, Rigaudiere N, Ghyselinck N, Dufaure JP, and Drevet JR. In vitro expression of a mouse tissue specific glutathione-peroxidase-like protein lacking the selenocysteine can protect stably transfected mammalian cells against oxidative damage. Biochem Cell Biol. 14: 125-131, 1996.
319. Vilardell J, Yu SJ, and Warner JR. Multiple functions of an evolutionarily conserved RNA binding domain. Mol Cell 5: 761-766, 2000.
320. Vinceti M, Wei ET, Malagoli C, Bergomi M, and Vivoli G. Adverse health effects of selenium in humans. Rev Environ Health 16: 233-251, 2001.
321. Voet D, Voet JG, and Pratt CW. Fundamentals of biochemistry. New York: John Wiley & Sons, 1999.
322. Walczak R, Carbon P, and Krol A. An essential non-Watson-Crick base pair motif in 3′UTR to mediate selenoprotein translation. RNA 4: 74-84, 1998.
323. Walder K, Kantham L, McMillan JS, Trevaskis J, Kerr L, De Silva A, Sunderland T, Godde N, Gao Y, Bishara N, Windmill K, Tenne-Brown J, Augert G, Zimmet PZ, and Collier GR. Tanis: a link between type 2 diabetes and inflammation? Diabetes 51: 1859-1866, 2002.
324. Wawrzynska L, Sakowicz A, Rudzinski P, Langfort R, and Kurzyna M. The conversion of thyroxine to triiodothyronine in the lung: comparison of activity of type 1 iodothyronine 5′deiodinase in lung cancer with peripheral lung tissues. Monaldi Arch Chest Dis 59: 140-145, 2003.
325. Wei WQ, Abnet CC, Qiao YL, Dawsey SM, Dong ZW, Sun XD, Fan JH, Gunter EW, Taylor PR, and Mark SD. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. Am J Clin Nutr 79: 80-85, 2004.
326. Weiss Sachdev S and Sunde RA. Selenium regulation of transcript abundance and translational efficiency of glutathione peroxidase-1 and -4 in rat liver. Biochem J 357: 851-858, 2001.
327. Wek RC, Jiang HY, and Anthony TG. Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans 34: 7-11, 2006.
328. Wenstrup D, Ehmann WD, and Markesbery WR. Trace element imbalances in isolated subcellular fractions of Alzheimer's disease brains. Brain Res 533: 125-131, 1990.
329. Whanger PD. Selenium and its relationship to cancer: an update dagger. Br J Nutr 91:11-28, 2004.
330. Whanger PD. Selenium and the brain: a review. Nutr Neurosci 4: 81-97, 2001.
331. Whanger PD. Selenocompounds in plants and animals and their biological significance. J Am Coll Nutr 21: 223-232, 2002.
332. Whanger PD. Selenoprotein W: a review. Cell Mol Life Sci 57: 1846-1852, 2000.
333. Williams CH, Arscott LD, Muller S, Lennon BW, Ludwig ML, Wang PF, Veine DM, Becker K, and Schirmer RH. Thioredoxin reductase two modes of catalysis have evolved. Eur J Biochem 267: 6110-6117, 2000.
334. Wilting R, Schorling S, Persson BC, and Bock A. Selenoprotein synthesis in archaea: identification of an mRNA element of Methanococcus jannaschii probably directing selenocysteine insertion. J Mol Biol 266: 637-641, 1997.
335. Wimmer U, Wang Y, Georgiev O, and Schaffner W. Two major branches of anti-cadmium defense in the mouse: MTF-1/metallothioneins and glutathione. Nucleic Acids Res 33; 5715-5727, 2005.
336. Wingler K and Brigelius-Flohe R. Gastrointestinal glutathione peroxidase. Biofactors 10: 245-249, 1999.
337. Wood MJ, Storz G, and Tjandra N. Structural basis for redox regulation of Yap1 transcription factor localization. Nature 430: 917-921, 2004.
338. Xia Y, Hill KE, Byrne DW, Xu J, and Burk RF. Effectiveness of selenium supplements in a low-selenium area of China. Am J Clin Nutr 81: 829-834, 2005.
339. Xu XM, Carlson BA, Mix H, Zhang Y, Saira K, Glass RS, Berry MJ, Gladyshev VN, and Hatfield DL. Biosynthesis of selenocysteine on its tRNA in eukaryotes. PLoS Biol 5: e4, 2006.
340. Xu XM, Mix H, Carlson BA, Grabowski PJ, Gladyshev VN, Berry MJ, and Hatfield DL. Evidence for direct roles of two additional factors, SECp43 and soluble liver antigen, in the selenoprotein synthesis machinery. J Biol Chem 280: 41568-41575, 2005.
341. Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T, and Yasuhara H. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial: Ebselen Study Group. Stroke 29: 12-17, 1998.
342. Yang M and Sytkowski AJ. Differential expression and androgen regulation of the human selenium-binding protein gene hSP56 in prostate cancer cells. Cancer Res 58:3150-3153, 1998.
343. Yant LJ, Ran Q, Rao L, Van Remmen H, Shibatani T, Belter JG, Motta L, Richardson A, and Prolla TA. The selenoprotein GPX4 is essential for mouse development and protects from radiation and oxidative damage insults. Free Radic Biol Med 34: 496-502, 2003.
344. Yeh JY, Beilstein MA, Andrews JS, and Whanger PD. Tissue distribution and influence of selenium status on levels of selenoprotein W. FASEB J 9: 392-396, 1995.
345. Yoo MH, Xu XM, Carlson BA, Gladyshev VN, and Hatfield DL. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J Biol Chem 281: 13005-13008, 2006.
346. Yu SY, Zhu YJ, Li WG, Huang QS, Huang CZ, Zhang QN, and Hou C. A preliminary report on the intervention trials of primary liver cancer in high-risk populations with nutritional supplementation of selenium in China. Biol Trace Elem Res 29: 289-294, 1991.
347. Zavacki AM, Mansell JB, Chung M, Klimovitsky B, Harney JW, and Berry MJ. Coupled tRNA(Sec)-dcpendent assembly of the selenocysteine decoding apparatus. Mol Cell 11: 773-781, 2003.
348. Zhang Y, Fomenko DE, and Gladyshev VN. The microbial selenoproteome of the Sargasso Sea. Genome Biol 6: R37, 2005.
349. Zhao L, Olubajo B, and Taylor EW. Functional studies of an HIV-1 encoded glutathione peroxidase. Biofactors 27: 93-107, 2006.
350. Zhao R and Holmgren A. Ebselen is a dehydroascorbate reductase mimic, facilitating the recycling of ascorbate via mammalian thioredoxin systems. Antioxid Redox Signal 6: 99-104, 2004.
351. Zhao R and Holmgren A. A novel antioxidant mechanism of ebselen involving ebselen diselenide, a substrate of mammalian thioredoxin and thioredoxin reductase. J Biol Chem 277: 39456-39462, 2002.
352. Zhao R, Masayasu H, and Holmgren A. Ebselen: a substrate for human thioredoxin reductase strongly stimulating its hydroperoxide reductase activity and a superfast thioredoxin oxidant. Proc Natl Acad Sci U S A 99: 8579-8584, 2002.
353. Zhong L, Arner ES, and Holmgren A. Structure and mechanism of mammalian thioredoxin reductase: the active site is a redox-active selenolthiol/ selenenylsulfide formed from the conserved cysteine-selenocysteine sequence. Proc Natl Acad Sci U S A 97: 5854-5859, 2000.
354. Zhong L and Holmgren A. Essential role of selenium in the catalytic activities of mammalian thioredoxin reductase revealed by characterization of recombinant enzymes with selenocysteine mutations. J Biol Chem 275: 18121-18128, 2000.
355. Zimmermann MB and Kohrle J. The impact of iron and selenium deficiencies on iodine and thyroid metabolism: biochemistry and relevance to public health. Thyroid 12: 867-878, 2002.
356. Zinoni F, Birkmann A, Stadtman TC, and Bock A. Nucleotide sequence and expression of the selenocysteine-containing polypeptide of formate dehydrogenase (formate-hydrogen-lyase-linked) from Escherichia coli. Proc Natl Acad Sci U S A 83: 4650-4654, 1986.